Tvardi Therapeutics Stock
Tvardi Therapeutics Stock price
Key metrics
Is Tvardi Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.
Tvardi Therapeutics Stock Analysis
Analyst Opinions
13 Analysts have issued a Tvardi Therapeutics forecast:
Analyst Opinions
13 Analysts have issued a Tvardi Therapeutics forecast:
Financial data from Tvardi Therapeutics
| Mar '25 |
+/-
%
|
||
| Revenue | 7.57 7.57 |
55%
55%
|
|
| Gross Profit | 5.02 5.02 |
61%
61%
|
|
| EBITDA | -28 -28 |
77%
77%
|
EBIT (Operating Income) EBIT | -28 -28 |
77%
77%
|
| Net Profit | -45 -45 |
63%
63%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Tvardi Therapeutics directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tvardi Therapeutics Stock News
Company Profile
Tvardi Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
| Head office | United States |
| CEO | Imran Alibhai |
| Founded | 2004 |
| Website | tvarditherapeutics.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
